N/A:IRME
IR-Med, Inc.
A biotechnology company advancing novel therapeutics and medical technologies to solve critical unmet patient needs.
Key Metrics
Investment Thesis
Bull Case
Investors might consider IRME if they believe in the transformative potential of its late-stage pipeline assets which could generate significant value upon regulatory approval; The company's focus on unmet medical needs provides a clear pathway to differentiation and market expansion once products reach commercialization; Strategic partnerships could provide milestone payments that help offset current cash burn while advancing development programs.
Bear Case
The stock faces severe liquidity risks given the negative operating cash flow of $1.4M and a massive retained earnings deficit of $16.7M that threatens long-term solvency; Revenue is currently zero indicating no commercial sales yet, making the company entirely dependent on external capital markets for survival; The lack of revenue growth over the past five years combined with persistent losses suggests high probability of dilution through equity issuances to fund operations.
About IR-Med, Inc.
IR-Med, Inc. (IRME) is a biotechnology firm focused on developing novel therapeutics and medical technologies to address critical unmet needs in patient care. The company leverages proprietary research and development initiatives to create innovative solutions across specialized healthcare markets. With significant investment in clinical-stage assets, the firm aims to transform healthcare delivery through advanced medical interventions.
Analysis
Management Discussion
The company reported a net loss of $1.9M in the latest period, showing improvement from previous years of -$4.7M and -$4.9M, suggesting potential stabilization in burn rates. Despite positive non-operating income of $3.8M likely from equity investments or tax benefits, core operations remain unprofitable with negative operating profit matching the net loss. The substantial retained earnings deficit of $16.7M highlights the capital-intensive nature of the business and the need for continued fundraising to sustain development activities.
Industry Overview
The biotechnology and medical device industry is characterized by high failure rates in drug development but offers substantial rewards for successful products addressing unmet needs. Companies in this sector require significant capital investment in research and development before achieving commercial viability, creating a volatile investment environment. Regulatory hurdles and long approval timelines mean that revenue recognition is typically delayed until late-stage clinical trials succeed.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $4.8M | $4.9M | $1.9M |
| Operating Income | $-4.8M | $-4.9M | $-1.9M |
| R&D | $1.9M | $2.1M | $710.0K |
| G&A | $2.1M | $2.0M | $1.0M |
| Stock-Based Comp | $1.3M | $1.7M | $485.0K |
| Depreciation | $10.0K | $17.0K | $21.0K |
| Other OpEx | $759.0K | $822.0K | $220.0K |
| Non-Operating Income | $9.5M | $9.8M | $3.8M |
| Pre-Tax Income | $4.7M | $4.9M | $1.9M |
| Income Tax | $9.5M | $9.8M | $3.8M |
| Continuing Ops | $-4.7M | $-4.9M | $-1.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-4.7M | $-4.9M | $-1.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-4.7M | $-4.9M | $-1.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $3.1M | $848.0K | $205.0K |
| Cash & Equivalents | $3.0M | $767.0K | $129.0K |
| Accounts Receivable | $55.0K | $81.0K | $76.0K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $237.0K | $151.0K | $46.0K |
| PP&E (Net) | $71.0K | $56.0K | $35.0K |
| Operating Leases | $155.0K | $84.0K | — |
| Other LT Assets | $11.0K | $11.0K | $11.0K |
| Total Assets | $3.3M | $999.0K | $251.0K |
| Current Liabilities | $662.0K | $473.0K | $545.0K |
| Accounts Payable | — | $64.0K | $114.0K |
| Other Current Liab | $530.0K | $249.0K | $243.0K |
| Long-Term Liabilities | $40.0K | $161.0K | $0 |
| Total Liabilities | $702.0K | $634.0K | $545.0K |
| Shareholders' Equity | $2.6M | $365.0K | $-294.0K |
| Paid-In Capital | $12.5M | $15.1M | $16.4M |
| Retained Earnings | $-9.9M | $-14.8M | $-16.7M |
| Total L&E | $3.3M | $999.0K | $251.0K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-4.7M | $-4.9M | $-1.9M |
| Non-Cash Adjustments | $1.3M | $1.6M | $604.0K |
| Working Capital Changes | $38.0K | $40.0K | $-91.0K |
| Cash from Operations | $-3.4M | $-3.2M | $-1.4M |
| Capital Expenditures | $50.0K | $2.0K | — |
| Cash from Investing | $-59.0K | $-2.0K | $0 |
| Cash from Financing | $3.6M | $1.0M | $750.0K |
| FX Effect | $-4.0K | $-1.0K | $-2.0K |
| Net Change in Cash | $187.0K | $-2.2M | $-638.0K |
| Beginning Cash | $2.8M | $3.0M | $767.0K |
| Ending Cash | $3.0M | $767.0K | $129.0K |
Frequently Asked Questions
How does IR-Med, Inc. make money?
Proprietary drug discovery and development programs targeting high-value therapeutic areas; Medical technology and device innovation for clinical applications; Strategic licensing partnerships and collaboration agreements with major pharmaceutical entities.
What are the main risks for IRME?
Significant operating losses and cash burn raising concerns about liquidity runway and ability to fund R&D without external financing; High regulatory risk associated with bringing new drugs or devices to market including FDA approval uncertainties; Dependence on success of specific clinical trials which could be delayed or fail despite substantial investment.
What is IRME's competitive advantage?
Proprietary intellectual property portfolio protecting novel therapeutic mechanisms and medical devices; Strong pipeline of assets in late-stage development with potential for milestone revenue; Access to specialized talent and strategic alliances within the biotechnology sector.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.